In Brief: Intelligent Medical Imaging/Coulter
This article was originally published in The Gray Sheet
Executive Summary
Intelligent Medical Imaging/Coulter: Sign agreement March 27 to terminate Coulter's exclusive sales and distribution agreement for IMI's MICRO21 automated microscope system. IMI will pay Coulter $4.2 mil. to end an arbitration proceeding initiated by IMI. IMI says the settlement "will be reflected as a one-time non-recurring charge" of $2.3 mil. in its 1996 financial statements. IMI will now market the microscope system through its 23 sales reps and distributors...
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.